Nenad Bogdanovic

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/522642/publications.pdf

Version: 2024-02-01

56 papers	2,882 citations	218677 26 h-index	189892 50 g-index
61 all docs	61 docs citations	61 times ranked	4509 citing authors

#	Article	IF	Citations
1	Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. Journal of Comparative Neurology, 1997, 379, 482-494.	1.6	436
2	Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium. Brain Pathology, 2008, 18, 484-496.	4.1	361
3	Staging/typing of Lewy body related Î±-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 635-652.	7.7	249
4	Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with Î³-secretase and regulates neuronal amyloid Î²-peptide levels. Alzheimer's Research and Therapy, 2017, 9, 57.	6.2	164
5	Assessment of Î²-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 309-320.	7.7	143
6	Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. European Journal of Human Genetics, 2001, 9, 437-444.	2.8	142
7	Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology, 2012, 79, 229-236.	1.1	138
8	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2006, 65, 740-757.	1.7	95
9	Clinical and Neuropathological Features of the Arctic APP Gene Mutation Causing Early-Onset Alzheimer Disease. Archives of Neurology, 2008, 65, 499.	4.5	91
10	Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family. Neuroscience Letters, 1994, 168, 254-256.	2.1	79
11	Assessment of Î±-Synuclein Pathology: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2008, 67, 125-143.	1.7	73
12	Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of AÎ²42 and Alzheimerâ€™s disease neuropathology. Acta Neuropathologica, 2010, 119, 543-554.	7.7	61
13	The Growth-Associated Protein GAP-43 Is Increased in the Hippocampus and in the Gyrus Cinguli in Schizophrenia. Journal of Molecular Neuroscience, 1999, 13, 101-110.	2.3	49
14	Finding of increased caudate nucleus in patients with Alzheimer's disease. Acta Neurologica Scandinavica, 2018, 137, 224-232.	2.1	47
15	Meta-analysis of Alzheimerâ€™s disease on 9,751 samples from Norway and IGAP study identifies four risk loci. Scientific Reports, 2018, 8, 18088.	3.3	47
16	Amyloid Î²-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain. NeuroReport, 2008, 19, 1085-1089.	1.2	45
17	Effects of Alcohol Abuse on Proliferating Cells, Stem/Progenitor Cells, and Immature Neurons in the Adult Human Hippocampus. Neuropsychopharmacology, 2018, 43, 690-699.	5.4	44
18	The Arctic AÎ²PP mutation leads to Alzheimerâ€™s disease pathology with highly variable topographic deposition of differentially truncated AÎ². Acta Neuropathologica Communications, 2013, 1, 60.	5.2	38

#	Article	IF	Citations
19	Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1276-1286.	6.4	38
20	Amyloid-Î² PETâ€"Correlation with cerebrospinal fluid biomarkers and prediction of AlzheimerÂ´s disease diagnosis in a memory clinic. PLoS ONE, 2019, 14, e0221365.	2.5	37
21	Preclinical Amyloid-Î² and Axonal Degeneration Pathology in Delirium. Journal of Alzheimer's Disease, 2016, 55, 371-379.	2.6	35
22	Analysis of Single Alzheimer Solid Plaque Cores by Laser Capture Microscopy and Nanoelectrospray/Tandem Mass Spectrometry. Biochemistry, 2006, 45, 9849-9856.	2.5	33
23	The Arctic amyloid-Î² precursor protein (AÎ²PP) mutation results in distinct plaques and accumulation of N- and C-truncated AÎ². Neurobiology of Aging, 2012, 33, 1010.e1-1010.e13.	3.1	31
24	Neuropeptide S- and Neuropeptide S receptor-expressing neuron populations in the human pons. Frontiers in Neuroanatomy, 2015, 9, 126.	1.7	31
25	Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 419-430.	0.8	31
26	Hippocampal granule cell loss in human chronic alcohol abusers. Neurobiology of Disease, 2018, 120, 63-75.	4.4	28
27	Cerebral ABC Transporter-common Mechanisms May Modulate Neurodegenerative Diseases and Depression in Elderly Subjects. Archives of Medical Research, 2014, 45, 738-743.	3.3	27
28	Environmental enrichment alters dentate granule cell morphology in oldestâ€old rat. Journal of Cellular and Molecular Medicine, 2009, 13, 1845-1856.	3.6	25
29	Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. Journal of Neural Transmission, 2015, 122, 957-972.	2.8	25
30	Reduced Sympathetic Response to Head-Up Tilt in Subjects with Mild Cognitive Impairment or Mild Alzheimer's Dementia. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 107-115.	1.3	23
31	Progression to dementia in memory clinic patients with mild cognitive impairment and normal Î²-amyloid. Alzheimer's Research and Therapy, 2019, 11, 99.	6.2	23
32	Hippocampal expression of cellâ€adhesion glycoprotein neuroplastin is altered in Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2019, 23, 1602-1607.	3.6	23
33	Identification of two novel synaptic Î³-secretase associated proteins that affect amyloid Î²-peptide levels without altering Notch processing. Neurochemistry International, 2012, 61, 108-118.	3.8	22
34	The Proteome of the Dentate Terminal Zone of the Perforant Path Indicates Presynaptic Impairment in Alzheimer Disease. Molecular and Cellular Proteomics, 2020, 19, 128-141.	3.8	22
35	Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimerâ€™s Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis. Journal of Alzheimer's Disease, 2019, 68, 571-582.	2.6	21
36	Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimerâ€™s disease variants: AÎ²PParc and PSEN1DE9. Molecular Psychiatry, 2021, 26, 5609-5619.	7.9	16

#	Article	IF	Citations
37	Effects of nucleus basalis lesion on muscarinic receptor subtypes. Experimental Brain Research, 1993, 97, 225-32.	1.5	15
38	Excellent outcome of pallidal deep brain stimulation in DYT6 dystonia: A case report. Journal of the Neurological Sciences, 2016, 366, 18-19.	0.6	9
39	Maturation and processing of the amyloid precursor protein is regulated by the potassium/sodium hyperpolarization-activated cyclic nucleotide-gated ion channel 2 (HCN2). Biochemical and Biophysical Research Communications, 2017, 483, 352-358.	2.1	8
40	Vitamin D Levels, APOE Allele, and MRI Volumetry Assessed by NeuroQuant in Norwegian Adults with Cognitive Symptoms. Journal of Alzheimer's Disease, 2021, 79, 311-321.	2.6	8
41	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. Scientific Reports, 2019, 9, 2460.	3.3	7
42	Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimerâ€™s disease. Translational Neurodegeneration, 2021, 10, 18.	8.0	6
43	Diagnostic accuracy and clinical applicability of the Swedish version of the 4AT assessment test for delirium detection, in a mixed patient population and setting. BMC Geriatrics, 2021, 21, 568.	2.7	6
44	Vitamin D in Alzheimerâ€™s Disease: Low Levels in Cerebrospinal Fluid Despite Normal Amounts in Serum. Journal of Alzheimer's Disease, 2022, 86, 1301-1314.	2.6	5
45	Multiple sclerosis and amyloid deposits in the white matter of the brain. Acta Neuropathologica, 1997, 93, 205-209.	7.7	4
46	Insulin-Independent and Dependent Glucose Transporters in Brain Mural Cells in CADASIL. Frontiers in Genetics, 2020, 11, 1022.	2.3	4
47	Microdissected Pyramidal Cell Proteomics of Alzheimer Brain Reveals Alterations in Creatine Kinase B-Type, 14-3-3-Î³, and Heat Shock Cognate 71. Frontiers in Aging Neuroscience, 2021, 13, 735334.	3.4	4
48	Serum Amyloidogenic Nanoplaques and Cytokines in Alzheimerâ€™s Disease: Pilot Study in a Small Naturalistic Memory Clinic Cohort. Journal of Alzheimer's Disease, 2022, 86, 1459-1470.	2.6	4
49	Amyloidogenic Nanoplaques in Cerebrospinal Fluid: Relationship to Amyloid Brain Uptake and Clinical Alzheimerâ€™s Disease in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 77, 831-842.	2.6	3
50	Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 608628.	3.4	3
51	Deep Brain Stimulation in Non-motor Symptoms of Neurodegenerative Diseases. , 0, , .		2
52	P3-041: BRAIN DEPOSITION OF PYROGLUTAMATE AÎ² IN AÎ² AMYLOIDOSIS. , 2014, 10, P643-P643.		0
53	Amyloidogenic nanoplaque levels are increased in the cerebrospinal fluid in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042828.	0.8	0
54	Confusion, cognitive impairment, and spinal cord compression caused by plasmacytoma: a case report. BMC Neurology, 2021, 21, 303.	1.8	0

#	Article	IF	Citations
55	Re: Glemsk og glemt. Tidsskrift for Den Norske Laegeforening, 2017, 137, 685-685.	0.2	0
56	Lack of fibrillar amyloid plaques but hypometabolism and astrogliosis in autosomal dominant variant AÃŸPParc Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 5471-5471.	7.9	0